| 0.375 -0.004 (-1.06%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.59 | 1-year : | 0.72 |
| Resists | First : | 0.5 | Second : | 0.62 |
| Pivot price | 0.4  |
|||
| Supports | First : | 0.33 | Second : | 0.27 |
| MAs | MA(5) : | 0.36 |
MA(20) : | 0.42 |
| MA(100) : | 0.59 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.4 |
D(3) : | 14.8 |
| RSI | RSI(14): 35.4 |
|||
| 52-week | High : | 20.65 | Low : | 0.33 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AIDX ] has closed above bottom band by 30.9%. Bollinger Bands are 45.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.4 - 0.4 | 0.4 - 0.4 |
| Low: | 0.36 - 0.36 | 0.36 - 0.36 |
| Close: | 0.37 - 0.38 | 0.38 - 0.38 |
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Fri, 09 Oct 2026
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Sat, 03 Oct 2026
20/20 Biolabs Inc : Maxim Group Cuts Target P - Moomoo
Fri, 02 Oct 2026
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026 - GlobeNewswire
Tue, 29 Sep 2026
FDA advisers voted favorably on a cancer blood test. 20/20 BioLabs will discuss what it could mean for its own test. - Stock Titan
Wed, 26 Aug 2026
20/20 BioLabs says its cancer blood test hit record quarterly revenue - Stock Titan
Wed, 22 Jul 2026
20/20 Biolabs Received Notice of Noncompliance - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 13 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 25 (%) |
| Held by Institutions | 4.2 (%) |
| Shares Short | 47 (K) |
| Shares Short P.Month | 106 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.12 |
| Profit Margin | -285 % |
| Operating Margin | -170.4 % |
| Return on Assets (ttm) | -62.4 % |
| Return on Equity (ttm) | -331.3 % |
| Qtrly Rev. Growth | 36.5 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.65 |
| PEG Ratio | 0 |
| Price to Book value | 2.88 |
| Price to Sales | 2.34 |
| Price to Cash Flow | -1.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|